Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)
| Autor: | Michael Pfeifer, Patrice Fardellone, Peyman Hadji, Helmut W. Minne, Angelo A. Licata, Vipul Devas, Pierre Bourgeois, Daiva Masanauskaite, Elizabeth Barrett-Connor |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Osteoporosis Administration Oral Ibandronic acid Drug Administration Schedule law.invention Patient satisfaction Rheumatology Randomized controlled trial law Internal medicine medicine Humans Prospective Studies Prospective cohort study Ibandronic Acid Osteoporosis Postmenopausal Aged Aged 80 and over Cross-Over Studies Alendronate Bone Density Conservation Agents Diphosphonates business.industry Middle Aged medicine.disease Crossover study Preference Regimen Treatment Outcome Patient Satisfaction Female business medicine.drug |
| Zdroj: | Joint Bone Spine. 75:303-310 |
| ISSN: | 1297-319X |
| DOI: | 10.1016/j.jbspin.2007.07.011 |
| Popis: | Patient preference strongly influences long-term medication use in chronic diseases such as postmenopausal osteoporosis.This 6-month, open-label, crossover, international study randomized 350 women with postmenopausal osteoporosis to monthly oral ibandronate 150mg for 3months followed by weekly alendronate 70mg for 12weeks, or vice versa.Of patients expressing a preference (93.1%), more preferred the monthly ibandronate regimen (70.6%) than the weekly alendronate regimen (29.4%). The monthly ibandronate preference rate was statistically significant (P0.0001). The most common reasons for ibandronate preference were ease of staying on treatment long-term (81.5%) and better lifestyle fit (75.4%). More women found the monthly ibandronate regimen more convenient (76.6%) than the weekly alendronate regimen (23.4%). The monthly ibandronate convenience rate was statistically significant (P0.0001). The safety profiles of the two regimens were similar.The strong patient preference for monthly ibandronate over weekly alendronate replicates previous study findings and may lead to improved treatment adherence in women with postmenopausal osteoporosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect